ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of giving ABT-888 together with
gemcitabine hydrochloride in treating patients with advanced solid tumors. ABT-888 may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used
in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888
together with gemcitabine hydrochloride may kill more tumor cells.